Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Acadia Pharma (ACAD) Tops Q4 EPS by 5c
February 24, 2021 4:23 PM ESTAcadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.42), $0.05 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $121.01 million versus the consensus estimate of $123.2 million.
Acadia delivered strong financial results in the fourth quarter and full year 2020, driven by... More
